...GmbH has the P2RX7 antagonist AFC-5128 in preclinical testing for neuropathic pain and multiple sclerosis. RaQualia Pharma Inc....

...TRPM8 antagonist in preclinical testing for interstitial cysitis, urinary tract disorders and overactive bladder (OAB). RaQualia Pharma Inc....

...At least two other P-CABs are also in the clinic for GERD: tegoprazan (RQ-04) from RaQualia Pharma Inc....
...Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Jiangsu Sinorda Biomedicine Co. Ltd., Suzhou, China RaQualia Pharma Inc....

...Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia...
...disclose details. RaQualia Pharma Inc. (JASDAQ:4579), Nagoya, Japan Maruho Co. Ltd., Osaka, Japan Business: Neurology Chris Lieu Maruho Co. Ltd. RaQualia Pharma Inc....

...develop potential clinical applications of induced pluripotent stem (iPS) cells. 11/18/2015 RaQualia Pharma Inc. (JASDAQ:4579) Nagoya University RaQualia...

...pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia...
...BioCentury, Nov. 25, 2013 & April 14, 2014). Asahi Kasei Pharma Corp. , Tokyo, Japan RaQualia Pharma Inc....

...share income from other markets with RaQualia. The companies could not be reached for details. RaQualia Pharma Inc....

...gastrointestinal diseases. CJ has rights to the product in several Asian countries, including China, from RaQualia Pharma Inc....

...structure-based drug discovery platforms to design therapeutics targeting protein-protein interactions. In 2013, it partnered with RaQualia Pharma Inc....

...to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia...
...skin structure infections (ABSSSIs) in adults (see BioCentury, May 2, 2011 & Nov. 24, 2014). RaQualia Pharma Inc....